US 11,723,923 B2
Methods of preparing T cells for T cell therapy
Arianne Perez, Santa Monica, CA (US); Marianna Sabatino, Santa Monica, CA (US); Steven A. Rosenberg, Bethesda, MD (US); and Nicholas P. Restifo, Bethesda, MD (US)
Assigned to Kite Pharma, Inc., Santa Monica, CA (US); and The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by Kite Pharma, Inc., Santa Monica, CA (US); and The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Aug. 6, 2019, as Appl. No. 16/533,109.
Application 16/533,109 is a continuation of application No. 15/299,394, filed on Oct. 20, 2016, abandoned.
Claims priority of provisional application 62/244,036, filed on Oct. 20, 2015.
Prior Publication US 2020/0206265 A1, Jul. 2, 2020
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01)
CPC A61K 35/17 (2013.01) [A61K 39/0011 (2013.01); A61K 39/00117 (2018.08); A61K 39/00118 (2018.08); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001109 (2018.08); A61K 39/001112 (2018.08); A61K 39/001113 (2018.08); A61K 39/001119 (2018.08); A61K 39/001124 (2018.08); A61K 39/001153 (2018.08); A61K 39/001156 (2018.08); A61K 39/001157 (2018.08); A61K 39/001161 (2018.08); A61K 39/001162 (2018.08); A61K 39/001166 (2018.08); A61K 39/001168 (2018.08); A61K 39/001171 (2018.08); A61K 39/001176 (2018.08); A61K 39/001181 (2018.08); A61K 39/001182 (2018.08); A61K 39/001184 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001189 (2018.08); A61K 39/001191 (2018.08); A61K 39/001192 (2018.08); A61K 39/001193 (2018.08); A61K 39/001194 (2018.08); A61K 39/001195 (2018.08); A61K 39/001197 (2018.08); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/727 (2013.01); C12N 2506/11 (2013.01)] 12 Claims
 
1. A method for culturing T cells for a T cell therapy while delaying or inhibiting maturation or differentiation of the T cells, comprising:
contacting, in a culture medium, one or more T cells with exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15) in the absence of exogenous Interleukin-2 (IL-2),
wherein the one or more T cells comprise CD4+ T cells, and the contacting is for 1 day to 10 days such that the CD4+ T cells, following such contacting, comprise a higher percentage of naive T cells and central memory T (Tcm) cells as compared to when the CD4+ T cells are contacted with exogenous IL-2 in the absence of exogenous IL-7 and exogenous IL-15.